Erlotinib EGFR inhibitors

OSI-774 - CP-358774 - CP 358774 - Tarceva



Trial Studied treatment Control Patients Size Study type Results NCT

Lung cancer (metastatic) - EGFR inhibitors in all type of patients

OPTIMAL erlotinibPlatinum-based CT165 (83/82) NCT00874419
EUTRACerlotinibPlatinum-based CTNA NCT00446225
TITANerlotinibPlatinum-based CTNA NCT00556322
TRIBUTE (Herbst)erlotinib + Platinum-based CTPlatinum-based CT1059 (526/533)
Gatzemeier erlotinib + Platinum-based CTPlatinum-based CT1159 (579/580)
Mok erlotinib + Platinum-based CTPlatinum-based CT114 (57/57)
SATURN (Cappuzzo)erlotinib + Platinum-based CTPlatinum-based CT889 (438/451) NCT00556712
Boutsikouerlotinib + Platinum-based CTPlatinum-based CT113 (52/61)
Lee erlotinib + Platinum-based CTPlatinum-based CT158 (78/80) NCT00550173
Stinchcombeerlotinib + Platinum-based CTPlatinum-based CT95 (51/44)
FASTACT-2 (Wu) erlotinib + Platinum-based CTPlatinum-based CT481 (226/255) NCT00883779



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons